SITE006-0124

SITE006 (GBR) › SITE006-0124

SITE006-0124

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2026-01-27

completed

AEs

5

Serious

1

Dropout signal

–

Adverse events

5

Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-11-06 (study day 95); relationship: RELATED

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-09-20 (study day 48); relationship: not assessed

mild assessed

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-09-11 (study day 39); relationship: not assessed

moderate assessed

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-09-05 (study day 33); relationship: NOT RELATED

moderate assessed

Grade 4 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-08-06 (study day 3); relationship: not assessed; serious criteria: life-threatening

severe serious assessed

Data queries

0

No data queries. Open queries would appear here for this patient.